This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Drug Therapy  • Drug Therapy, Other  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

A Warning and a Challenge

Joel D. Trachtenberg, MD; Merle A. Sande, MD

JAMA. 2002;288:239-241.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Two decades after the recognition of the human immunodeficiency virus (HIV) epidemic, the potential for widespread treatment of HIV infection is now at a pivotal, yet precarious time. In the United States and Europe, patients with HIV infection are living longer without acquired immunodeficiency syndrome (AIDS)–defining illnesses, new highly active antiretroviral therapy (HAART) strategies are being developed and tested, and resistance testing is becoming a new standard for managing therapy after failure with HAART. Yet in much of the developing world, most notably sub-Saharan Africa, HIV and AIDS are devastating innumerable communities. At a time when the introduction of HAART in Africa is in its infancy, 2 articles in this issue of THE JOURNAL illustrate the crucial role the nonnucleoside reverse transcriptase inhibitors (NNRTIs), as well as the implications of NNRTI resistance, will play in the treatment of HIV in both developed . . . [Full Text of this Article]

Author Affiliations: Department of Internal Medicine, University of Utah, Salt Lake City (Drs Trachtenberg and Sande); and Academic Alliance for AIDS Care and Prevention in Africa, Makerere University, Kampala, Uganda (Dr Sande).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Dual vs Single Protease Inhibitor Therapy Following Antiretroviral Treatment Failure: A Randomized Trial
Scott M. Hammer, Florin Vaida, Kara K. Bennett, Mary K. Holohan, Lewis Sheiner, Joseph J. Eron, Lawrence Joseph Wheat, Ronald T. Mitsuyasu, Roy M. Gulick, Fred T. Valentine, Judith A. Aberg, Michael D. Rogers, Cheryl N. Karol, Alfred J. Saah, Ronald H. Lewis, Laura J. Bessen, Carol Brosgart, Victor DeGruttola, John W. Mellors, and for the AIDS Clinical Trials Group 398 Study Team
JAMA. 2002;288(2):169-180.
ABSTRACT | FULL TEXT  

Time Trends in Primary HIV-1 Drug Resistance Among Recently Infected Persons
Robert M. Grant, Frederick M. Hecht, Maria Warmerdam, Lea Liu, Teri Liegler, Christos J. Petropoulos, Nicholas S. Hellmann, Margaret Chesney, Michael P. Busch, and James O. Kahn
JAMA. 2002;288(2):181-188.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Trends of prevalence of primary HIV drug resistance in Germany
Sagir et al.
J Antimicrob Chemother 2007;60:843-848.
ABSTRACT | FULL TEXT  

AIDS and Antiretroviral Drugs in South Africa: Public Health, Politics, and Individual Suffering: A Review of Brian Tilley's It's My Life
Noah
J Law Med Ethics 2003;31:144-148.
 

More on Transmission of Drug-Resistant Virus
AIDS Clin Care 2002;2002:3-3.
FULL TEXT